Please ensure Javascript is enabled for purposes of website accessibility

This Pharma Can Breathe New Life Into Your Portfolio

By Patrick Bafuma - Apr 2, 2021 at 6:50AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Will future Tyvaso revenue growth push United Therapeutics to new heights?

Investors largely shrugged off the most recent earnings report from United Therapeutics (UTHR 0.92%), a pharma company that focuses on pulmonary hypertension. Sometimes, however, past financial results can cloud the vision a company has for its future. The savviest investors look to the past and to the future when deciding whether or not to make a purchase. I think that the growth potential United Therapeutics offers may prove to be be a breath of fresh air for shareholders.

Poised for growth

While revenue for the company's leading product for pulmonary hypertension, Remodulin, was down 12% from fiscal 2019 to fiscal 2020 (from $587 million to $516.7 million) due to generic competition coming to market in 2018, another pulmonary hypertension treatment, Tyvaso, gained 16% in in that time, from $415.6 million to $483.3 million. Management is currently seeking expanded labeling for Tyvaso for pulmonary hypertension and interstitial lung disease, hoping to double the number of patients taking the drug within 18 months. A decision from the U.S. Food and Drug Administration (FDA) is due in April.

A white flower blooming in grass.

Image source: Getty Images.

It gets better

In 2022, it could get even better for this laser-focused company. Results from a study evaluating Tyvaso for pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD) will likely be out in the second half of 2022, and if they're positive, an additional 100,000-plus patients could be added to Tyvaso's addressable market -- tripling the current number.

United Therapeutics is also launching the Remunity pump in 2021. This delivery device for Remodulin is analogous to insulin pumps for diabetes patients. Investors will want to keep an eye on this product launch, because its success will likely revive sales of the Remodulin franchise, whose sales were declining due to generic competition since 2018. If United Therapeutics can approach the market penetration of insulin pumps for type 1 diabetics (which is about 30% of the U.S.), I think that the company should be able to stabilize if not increase Remunity sales, while growing hardware and consumables sales. For comparison, the hardware and consumables market has been lucrative for the type 1 diabetes market, having produced 70% profit margins for insulin pump maker Dexcom (DXCM -3.03%), there is little reason to think these kinds of margins won't also be the case for United Therapeutics.

Bringing combined growth and value to your portfolio

With a $7.5 billion market cap, a price-to-earnings (P/E) ratio of 14, and sales of $1.483 billion in fiscal 2020, United Therapeutics seems cheap given its strong potential for an expanded addressable market. Healthcare investors looking for an under-the-radar growth stock on the cheap should consider adding United Therapeutics to their watch list.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

United Therapeutics Corporation Stock Quote
United Therapeutics Corporation
$185.13 (0.92%) $1.69
DexCom, Inc. Stock Quote
DexCom, Inc.
$324.60 (-3.03%) $-10.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.